🇲🇽 GU Oncologist @incanMx 2025-/ Postdoc @CityofHope 2023-2025/ @JCOGO_ASCO Editorial Fellow 2022-2023
INCan
Joined April 2018
- Tweets976
- Following1.8K
- Followers2.6K
- Likes11.2K
Pinned Tweet
I had a chance to talk at @ASCO Connection about myself, my unusual career path coming from 🇲🇽, and the impact that mentorship has had on my professional development.
Special thanks to @ASCOTECAG for the opportunity to share my story!
connection.asco.org/magazine… – at Cuauhtémoc, Distrito Federal
Regina Barragan-Carrillo retweeted
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
Regina Barragan-Carrillo retweeted
Thrilled to have joined @DanaFarber and to be working with an inspiring leader in oncology, @DrChoueiri. Delighted to serve as a faculty medical oncologist and Co-Director of the @Harvard Cancer Consortium #ProstateCancer Program. Excited for this new chapter!
Regina Barragan-Carrillo retweeted
You may have caught the great conversation with @batraatulonc that I had on the #ASCODailyNews Podcast, where we covered worldwide implications of plenary abstracts from #ASCO26. Now I had a chance to talk with @incanMX faculty member @ReginaBarCar on a similar topic, extending the discussion around regional impact from #Asia to #LATAM! Have a listen as we distill (in line with the vision of previous @ASCO President Eric Small) how data does (or does not!) percolate into different settings ...
🎙 @montypal of @cityofhope and @ReginaBarCar of @incanMx discuss the complexities of translating breakthrough #ASCO26 research into day-to-day practice in Latin America on a new episode of the #ASCODailyNews Podcast: bit.ly/4xU8Bb2
Regina Barragan-Carrillo retweeted
🎙 @montypal of @cityofhope and @ReginaBarCar of @incanMx discuss the complexities of translating breakthrough #ASCO26 research into day-to-day practice in Latin America on a new episode of the #ASCODailyNews Podcast: bit.ly/4xU8Bb2
Regina Barragan-Carrillo retweeted
#ScienceLink #ASCO26 #Chicago2026 #Genitourinarios
Chicago 2026: Lo más destacado en Tumores Genitourinarios
Dra. Regina Barragán (@ReginaBarCar) y Dr. Augusto Ferreyra (@FerreyraCamacho)
buff.ly/aTGoCYI
Regina Barragan-Carrillo retweeted
For those not as familiar with the @ASCO Daily News Podcast, this is a great one to start with! Cheers to @KimmieNgMD for a brilliant conversation that led to an Award of Distinction on @commawards! @GCarroll147 @cityofhope @danafarber #ASCO26
dailynews.ascopubs.org/do/po…
Regina Barragan-Carrillo retweeted
Single arm phase II investigator initiated trials (IITs) used to be easier. Thats how I started my career. Budgets were low and institutions allowed you to open underfunded trials. Now due to a variety of factors the per patient costs of even single arm trials are very high, especially in oncology. Which means either you need industry support or NIH funding.
Industry funded IITs are the most common type but they naturally have to be of some interest to industry for you to get drug and funds. And that means collaborative development with some give and take.
NIH Grants and NIH cooperative group mechanism (ECOG, SWOG , ALLIANCE) is the second route. It’s quite a bit more tougher because there will be a lot of review and funding may not be sufficient. So often you need industry support in addition. But it is a good mechanism for truly important ideas to be tested.
Philanthropy and non profit foundations are a third path. More limited in number of trials that are supported this way.
I think if you are motivated single arm phase II IITs are a good way to start a clinical trial career. I strongly recommend that route. Much easier than trying to launch a career with a phase III. It builds your credibility and makes it more likely that in the future you will be in a competitive position to lead a phase III trial.
Start with a good clinical question and then work with pharma/NIH mechanisms to get a concept that’s mutually acceptable.
Phase I IITs may be a little difficult for young investigators to lead unless you have been involved in the lab development of the drug.
Regina Barragan-Carrillo retweeted
Could not be prouder of @ReginaBarCar who delivered a terrific talk at #SWOGSpring2026 related to #kidneycancer in #LATAM and associated research priorities. Fully agree with the approach/strategy she suggests. We miss her at @cityofhope but great to see her doing great things at @incanMX! @Nora_Sobrevilla @Betzabe100
Regina Barragan-Carrillo retweeted
If being the best makes you bad, then so be it. #OpeningDayLA
Regina Barragan-Carrillo retweeted
⭐️Key Takeaways-Community Oncologists @ASCO #GU26
@ReginaBarCar +Dr.Shameem 🗣️
🔹 KEYNOTE-B15/EV-304: EV+pembro beats chemo in #MIBC
🔹 ctDNA/utDNA in MIBC
🔹 Prostate Ca: OS wins with radium-223 + enzalutamide, PARP combos in BRCA+, NGS 🔑 #OncTwitter
oncupdates.com/video-podcast…
Regina Barragan-Carrillo retweeted
Estamos listos para este nuevo reto 🙌🏻
We are ready for this new challenge 🙌🏻
Siguiente destino: Mérida 🇲🇽🦩
Next stop: Merida 🇲🇽🦩
📍Centro Internacional de Congresos de Yucatán
🗓️ 11 - 15 noviembre 2026
#SMU26 #JuntosTrascendemos
Regina Barragan-Carrillo retweeted
Our @OncoAlert 🚨Faculty @weoncologists 🇺🇸of OncoAlert with his TOP picks of #ProstateCancer Trials Presented at #ESMO25 🇩🇪 for the OncoAlert TOP3 Series post ESMO 2025, more to come..
THESE and More GREAT GU TRIALS to be Discussed next week in Nashville for #UromigosLive
✅EMBARK
✅CAPItello-281
✅PETRANHA
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @cdanicas @yekeduz_emre @DrYukselUrun
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88
Regina Barragan-Carrillo retweeted
💫🌟Honored & proud to lead the #GUCancer Faculty for #ESMO25 with @ReginaBarCar 🇲🇽 & @weoncologists 🇺🇸 as we unveil our TOP 🔟 GU Abstracts 🚀 @OncoAlert
Grateful for the collaboration & excited to share the stage with brilliant minds like
🇨🇭 Dr. Gillessen
🇺🇸Dr. Agarwal
🇺🇸Dr. Zhang
🇺🇸Dr. Rini
🇺🇸Dr. Grivas
🇬🇧 Dr. Chowdhury
🇪🇸 Dr. Grande in the Senior Faculty Band!
🔹 PSMAaddition,
🔹️ENZARAD,
🔹️CAPItello-281,
🔹️EMBARK
🔹 RAMPART,
🔹️OPTIC RCC
🔹 KEYNOTE-905,
🔹️ IMvigor011,
🔹️ALPACA & more!
See you in Berlin 🇩🇪
#ProstateCancer #KidneyCancer #BladderCancer #PenileCancer
#GUonc #OncoResearch #DelphiPicks
The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.
✅ LBA6 — Phase 3 trial of [¹⁷⁷Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAaddition)
✅LBA86 — Randomised phase 3 trial of ADT with radiation therapy with or without enzalutamide for high-risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)
✅2383O — Capivasertib + abiraterone vs placebo + abiraterone in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281
✅LBA87 — EMBARK: OS with enzalutamide in biochemically recurrent prostate cancer
✅LBA93 — RAMPART: Adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma
✅2591O — Efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma: results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker
✅LBA2 — Perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase 3 KEYNOTE-905
✅LBA7 — Disitamab vedotin plus toripalimab vs chemotherapy in first-line locally advanced or metastatic urothelial carcinoma with HER2-expression
✅LBA8 — IMvigor011: A phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer
✅LBA109 — DISCUS: A phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer
✅LBA111 — Randomized comparison of upfront MRI versus transurethral resection for staging new bladder cancers: final survival analysis from the BladderPath trial
✅LBA37 — Avelumab in locally advanced or metastatic penile cancer patients unfit for platinum-based chemotherapy or progressed on or after platinum-based chemo (ALPACA)
Senior Faculty
🇨🇭 Dr. Gillessen
🇺🇸Dr. Agarwal
🇺🇸Dr. Zhang
🇺🇸Dr. Rini
🇺🇸Dr. Grivas
🇬🇧 Dr. Chowdhury
AF Collaborators
🇧🇷 Dr. Melao
🇮🇳 Dr. Jain
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @ReginaBarCar
Regina Barragan-Carrillo retweeted
Excited to share our study on exercise referral in oncology among physicians in #LatinAmerica #ASCOQLTY25
85% reported no formal education—> a key gap
@ASCO #ExerciseOncology
@crisbergerot @NarjustFlorezMD @BourlonMaite @LuciaViola9 @ReginaBarCar @EnriqueSoto8 @fitaftercancer
Regina Barragan-Carrillo retweeted
Honored to present my poster at ASCO Quality Care Symposium 2025 in Chicago this week!
It was a great opportunity to share our work on global disparities in clinical trial avaiability!
I am truly grateful for the support of my mentors @montypal, @mzugman and @ReginaBarCar
Regina Barragan-Carrillo retweeted
See you in Berlin for #ESMO25!
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .
We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials. From the podium to your smartphone: direct, no fluff and always relevant.
#OncoAlertAF
🇺🇸 @WeOncologists
🇧🇪 @ElisaAgostinett
🇦🇷 @nataliagandur
🇮🇹 @to_be_elizabeth
🇫🇷 @acampsmalea
🇺🇸 @BRicciutiMD
🇯🇵 @HHorinouchi
🇺🇸 @Abdallah81MD
🇧🇷 @bavilima
🇧🇷 @FernandoOnco
🇺🇸 @realbowtiedoc
🇹🇷 @Erman_Akkus
🇮🇹 @Lucarecco
🇮🇹 @GaiaGriguolo
🇷🇸 @JankovicK
🇪🇸 @MarioBalsaMD
🇪🇸 @DrMirallas
🇺🇸 @GIMedOnc
🇹🇷 @UOzkerim
🇮🇳 @DrRishabhOnco
🇲🇽 @ReginaBarCar
Ping Faculty
@matteolambe @PGrivasMDPhD @E_de_Azambuja @amerseburger @Icro_Meattini @montypal @crisbergerot @aftimosp
Regina Barragan-Carrillo retweeted
Proud to host On the Edge of Breakthrough, a podcast series from @cityofhope , where we spotlight the scientists, clinicians, and innovators driving the future of cancer care.
From AI-powered research and cellular therapy to metabolism, surgical innovation, and health equity, each episode offers a deep dive into the breakthroughs shaping oncology today—and tomorrow.
🎧 Recent highlights include:
Dr. @LorettaEMD on lung cancer and environmental health
Dr. @kmmahuron on expanding TIL therapy
Dr. @CharlesMBrenner on metabolism and cancer risk
Dr. Linda Malkas on the development of AOH1996
Whether you're a researcher, clinician, or advocate, this series is for anyone passionate about advancing cancer care through science, collaboration, and hope.
🔗 Explore the full series: cityofhope.org/research/rese…
#CancerResearch #OncologyInnovation #CityOfHope #PodcastSeries #PrecisionMedicine #TeamScience
